Sawai Launches Six Generic Drugs with 14 Strengths

Dec. 13. 2018

Osaka, Japan – December 13, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of six compounds with 14 strengths of generic drugs. They will be launched sequentially beginning tomorrow. Sawai’s product line now includes 310* compounds with 756 strengths. Among the six compounds, four compounds, “Mirtazapine”, “Atomoxetine Hydrochloride”, “Tramadol Hydrochloride and Acetaminophen” and “Capecitabine", will be launched for the first time as generics.

* TOARASET® Combination Tablets are Tramadol Hydrochloride and Acetaminophen, and are counted as one compound.
* FREWELL® Combination Tablets are Norethisterone and Ethinylestradiol, and are counted as one compound.

The list of new products:

1. MIRTAZAPINE OD Tablets 15 mg [SAWAI] and 30 mg [SAWAI], MIRTAZAPINE Tablets 15 mg [SAWAI] and 30 mg [SAWAI]

Generic name: Mirtazapine
Indications: Depression and depressive state
Brand products: REFLEX® TABLETS 15 mg and 30 mg, REMERON® Tablets 15 mg and 30 mg
Striking features: Orally disintegrating (OD) tablets are the first dosage form for Mirtazapine. Sawai aimed to improve patient convenience by developing OD tablets which are taken at bedtime without water. In addition, “Product name” and “Strength” are printed on the tablets, allowing the product to be identified even after removing from blister packs.

2. ATOMOXETINE Capsules 5 mg [SAWAI], 10 mg [SAWAI], 25 mg [SAWAI] and 40 mg [SAWAI]

Generic name: Atomoxetine Hydrochloride
Indications: Attention-deficit and hyperactivity disorder (ADHD)
Brand products: Strattera® Capsules 5mg, 10 mg, 25 mg and 40 mg
Striking features: The capsules are miniaturized and are printed with the “Generic name” and “Strength”.

3. TOARASET® Combination Tablets [SAWAI]

Generic name: Tramadol Hydrochloride and Acetaminophen
Indications: Non-cancerous chronic pain and pain after tooth extraction that cannot be managed by treatments with non-opioid analgesics
Brand products: TRAMCET® Combination Tablets
Striking features: The “Product name” is printed on both sides of tablet. “Therapeutic category”, “Product name” and “Generic name and Strength” are indicated on the blister pack.

4. ROPINIROLE Extended-release Tablets 2 mg [SAWAI] and 8 mg [SAWAI]

Generic name: Ropinirole Hydrochloride
Indications: Parkinson’s disease
Brand products: ReQuip® CR Tablets 2 mg and 8 mg

5. FREWELL® Combination Tablets LD [SAWAI] and ULD [SAWAI]

Instruction card
Generic name: Norethisterone and Ethinylestradiol
Indications: Dysmenorrhea
Brand products: LUNABELL® Tablets LD and ULD
Striking features: The blister pack can be set to the instruction card. And easy for disposal.

6. CAPECITABINE Tablets 300 mg [SAWAI]

Generic name: Capecitabine
Indications: Inoperable or recurrent breast cancer, colorectal cancer, gastric cancer
Brand products: XELODA® Tablets 300
Striking features: Sawai is launching the first generic of this product. Since anti-cancer treatment can be lengthy, generic drugs play an important role to help patients financially.


A special feature of packages:

Crushable packaging box

Push from above with both hands


This box can be easily crushed upon disposal. This feature applies to MIRTAZAPINE OD Tablets, MIRTAZAPINE Tablets, and TOARASET® Combination Tablets.